 |
|
|
|
|
| |
 |
|
|
| |
Boston Millennia Partners’ portfolio reflects Millennia’s commitment towards building enduring, large-scale businesses that have the potential to provide superior financial returns to our investors. Millennia’s portfolio is comprised of a diversified group of firms each positioned with the potential to become leaders in their respective market segments. We invite you to use the links below to learn more about each of those portfolio companies. |
|
| |
|
|
| |
| |
|
| |
|
|
28202 Cabot Road
Laguna Niguel, CA 92677
Phone: 949-347-2446
Fax: 949-247-9720
|
|
| |
| |
Novalar Pharmaceuticals Inc., privately held, is developing a novel product in the area of local dental anesthesia. A typical side effect in local dental anesthesia is a lingering numbness in the lips, cheek and tongue. The lingering “soft tissue” anesthesia may last for several hours post-procedure, causing patients to lose work hours or accidentally bite into numbed soft tissue. The company’s product is a local anesthetic reversal agent (LARA).
Novalar seeks to accelerate soft tissue recovery time by up to 75% by administering an injection of LARA into the soft tissue upon completion of a procedure requiring local anesthetic. LARA consists of a small dose of phentolamine-mesylate, a drug currently approved by the FDA, in high-dose formulation, for the treatment of hypertension in pheochromocytoma patients.
Reports indicate that as much as 90% of dental procedures require local anesthetic, and at least 75% of local dental anesthetics contain a vasoconstrictor, a compound such as epinephrine that constricts blood vessels around the point of injection. There are roughly 250 million office visits a year where dental anesthesia is given, and roughly 2/3 of these visits are candidates for LARA. The vasoconstrictor helps prevent the dissipation of an anesthetic thus prolonging its numbing effects for up to several hours. Novalar seeks to accelerate recovery in the soft tissue in procedures where patients would otherwise be inconvenienced by the prolonged anesthetic effect.
|
|
| |
|
| Millennia Team |
Rob Jevon
|
|
| Investment Date |
May 2002 |
|
| Visit the Website |
http://www.novalar.com/ |
|
| Related News |
Chicago, IL - February 27, 2009
Novalar™ Announces the Launch of OraVerse™ the First Dental Anesthesia Reversal Agent
San Diego, CA - August 12, 2008
Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse™ a Local Anesthetic Reversal Agent
San Diego, CA – December 18, 2007
Novalar Strengthens Senior Management Team with Key Appointments.
San Diego, CA - November 1, 2007
Novalar Raises $30 Million in Series D Financing
San Diego, CA - August 22, 2007
Novalar Appoints Steven J. Semmelmayer to its Board of Directors
San Diego, CA - July 25, 2007
NOVALAR announces exclusive license to develop and commercialize antibiotic fiber for root canal therapy
San Diego, CA - June 19, 2007
NOVALAR announces acceptance of NV-101 New Drug Application for filing by FDA
San Diego, CA - April 10, 2007
Novalar Submits New Drug Application for Anesthetic Reversal Agent NV-101
San Diego, CA - March 20, 2007
Novalar Presents Results from Successful Studies of Anesthetic Reversal Agent at International Association of Dental Research Annual Meeting
San Diego, CA - November 15, 2006
Positive Phase 2 Pediatric Study Results
San Diego, CA - October 3, 2006
Novalar Announces Positive Phase 3 Results for Novel Dental Anesthesia Reversal Agent
San Diego, CA - March 16, 2006
Novalar Initiates Pivotal Phase 3 Studies for Novel Dental Anesthesia Reversal Agent
San Diego, CA - March 11, 2005
Novalar Pharmaceuticals Raises $27 Million in Series C Financing
|
|
|
|
|
|
|
|
|
|
